Investigating the Therapeutic efficacy of GLA-IGF2 fusion enzyme with Pharmacological Chaperone ACK170 for Fabry disease
碩士 === 國立陽明大學 === 臨床醫學研究所 === 107 === Fabry disease is an X-linked inherited lysosomal storage disease with the global incidence rate from 1/40000 to 1/60000. Fabry disease is caused by mutations of GLA gene which encodes alpha-galactosidase A (α-GAL) enzyme. Complete deficiency of this enzyme alter...
Main Authors: | Yu-Ting Lin, 林妤庭 |
---|---|
Other Authors: | Dau-Ming Niu |
Format: | Others |
Language: | zh-TW |
Published: |
2018
|
Online Access: | http://ndltd.ncl.edu.tw/handle/32d49v |
Similar Items
-
To develop a new pharmacological chaperones therapeutic strategy for Fabry disease by using Fabry disease mice model
by: Ssu-Chia Wang, et al.
Published: (2018) -
The endoplasmic reticulum chaperone GRP170: from immunobiology to cancer therapeutic
by: Hongxia eWang, et al.
Published: (2015-01-01) -
Functional evaluation of a novel GLA causative mutation in Fabry disease
by: Ping Li, et al.
Published: (2019-09-01) -
Novel GLA Mutation Promotes Intron Inclusion Leading to Fabry Disease
by: Patrícia Varela, et al.
Published: (2019-09-01) -
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests
by: Cammisa Marco, et al.
Published: (2011-10-01)